CD33

Across TCGA pan-cancer cohorts, CD33 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CD33 data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher CD33 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CD33 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

LUSC, COAD, and UCEC are the cancer types where CD33 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	III,IV	0.199	0.678	<.001	36	view →
COAD	OS	Median	All	0.126	0.809	<.001	26	view →
UCEC	DFS	Median	All	0.962	0.625	.019	22	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
BLCA	OS	Median	II,III,IV	1.000	0.414	.038	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CD33–LUSC (OS)

Open the LUSC breakdown →